A.Ahmed,PhD

👩🏽‍🔬PhD @waynestateCLAS, PD @UMichUrology and now in biotech

[Aditya Shreenivas MD MS @AdityaSunavs]

Was worth the wait, sharing our real-world analysis of HER2 across solid tumors! 206750 tumors profiled by @carisls for ERBB2 alterations, revealing complex relationships between ERBB2 alterations and HER2 IHC expression. Forever grateful to @Dr_R_Kurzrock for her mentorship.

[A.Ahmed,PhD @AAAPhD1]

@pharmacocaitlin Congratulations Caitlin! I know you will do great work in moving the needle in the right direction.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

A MUST-READ!

This is probably one of my most important papers where I try to teach how to fish rather than offer fish.

How I Read a Clinical Trial Report?

BG’s primer for Busy Clinicians.

Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.

https://t.co/HJhZlsBpU2

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO
https://t.co/tDi3kbxdvX
#PrecisionMedicine #hemeonc @TempusAI

[A.Ahmed,PhD @AAAPhD1]

https://t.co/5EiLZPJRel

[International Society of Liquid Biopsy @isliquidbiopsy]

ctDNA in colorectal cancer is no longer “one test, one time.” A recent @NatureRevCancer Clinical Oncology review summarizes how liquid biopsy is becoming a longitudinal tool, supporting diagnosis, treatment selection, response monitoring, resistance profiling, and postoperative risk stratification.

🧬 In metastatic CRC, plasma ctDNA can capture tumour heterogeneity better than a single-site biopsy and allows serial tracking of clonal evolution, useful for resistance monitoring and for anti-EGFR selection/rechallenge.

🩸 In earlier-stage disease, postoperative ctDNA is a strong prognostic marker and is being evaluated to guide adjuvant escalation or de-escalation strategies.

⚠️ Interpretation still needs rigor, ctDNA detection depends on tumour fraction and shedding (so “negative” isn’t always “no disease”), and clonal hematopoiesis (CHIP) can drive false positives.

📌 Take-home: not tissue vs plasma—smart integration with standardized workflows will be key for clinical adoption.

@UmbertoMalapel1
@ElJanLe @DrYukselUrun @drgandara @MJOSESERRANO19
@ChristianRolfo @ErulEnes @ReduzziCarol @RobertoBoreaMD
@jlb_islb @ddemiguelperez @PasqualePisapia
@Al3ssandroRusso @eleonora_nicolo @DrMirallas

#ISLB #LiquidBiopsy #ctDNA #ColorectalCancer #MRD #PrecisionOncology

[International Society of Liquid Biopsy @isliquidbiopsy]

Circulating tumor cells (CTCs) are back in the spotlight 🩸
In this editorial in @jlb_islb outlines how CTCs can move from fascinating biology to routine clinical tools. @MJOSESERRANO19 @CtcLaboratory

✅ CTCs capture spatial/temporal tumour heterogeneity, immune escape and resistance mechanisms that may be missed by ctDNA alone

✅ Emerging rare-cell technologies can process larger blood volumes and enable single-cell genomic & proteomic profiling

✅ ISLB call for harmonised pre-analytics, clear CTC definitions and standardized reporting so counts & phenotypes can be compared across trials and used for prognosis, treatment selection and MRD monitoring

Together with ctDNA, CTCs are poised to play a complementary role in next-generation liquid biopsy strategies.

#CTC #LiquidBiopsy #JLB #PrecisionOncology

@UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19
@ChristianRolfo @DrYukselUrun @ErulEnes @ReduzziCarol @RobertoBoreaMD
@jlb_islb @ddemiguelperez @PasqualePisapia
@Al3ssandroRusso @eleonora_nicolo

[Mouadh Barbirou @BarbirouMouadh]

Genesis CTC workflow

[Dr. Catharine Young @DrCatharineY]

I fear the public will never truly realize the immense damage done to our scientific research system and its consequences. A loss of ~$4.5 billion in frozen or cancelled grants with at least 148 impacted clinical trials = 138,000 patients due to be enrolled or already enrolled.

[Dr. Laurel Gabard-Durnam @laurel_joy_gd]

If you have tenured & can share your application materials, I would love to build this section out on our Resources webpage! Please email me for eternal gratitude and as always, credit on the site: [email protected] Please RT to help me reach folks to share!

[Lucia Borriello @luciaborriell]

🚨 Exciting Opportunity Alert! 🚨

Are you passionate about understanding why cancer patients relapse and uncovering the secrets of tumor dormancy and metastasis?

Join our dynamic lab @templemedschool and @FoxChaseCancer

✨ Please RT to spread the word! ✨

[Brian Crompton @bdcrompton]

So excited that years of work validating the prognostic value of ctDNA in pediatric sold tumors has led to this effort @BostonChildrens @DanaFarber and @broadinstitute to stand up a clinical liquid test specific for pediatric oncology. https://t.co/KOhsZhEK2i

[A.Ahmed,PhD @AAAPhD1]

@mgoudaMD Congratulations Mohamed!!

[Pat Adams @PathologyPat]

Multinucleated giant cells are hallmarks of ovarian aging with unique immune and degradation-associated molecular signatures | PLOS Biology https://t.co/JOsKowPo4w

[Prof. Nikolai Slavov @slavov_n]

Cell size varies by many orders of magnitude.

The mechanisms that generate and maintain this extraordinary diversity of sizes remain incompletely understood.

[Pat Adams @PathologyPat]

RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection | bioRxiv https://t.co/FjLAUbp71r

[Peter W. Laird (@peterwlaird.bsky.social) @peterwlaird]

https://t.co/SjaFixzWbF

[Pat Adams @PathologyPat]

Fragment dispersity index analysis of cfDNA fragments reveals chromatin accessibility and enables early cancer detection: Cell Reports Methods https://t.co/DbgMOxDqB6

[nature @Nature]

Researchers funded by the NIH will be required to make their scientific papers available to read for free as soon as they are published

https://t.co/K704HXnyoD

[Society for Basic Urologic Research | SBUR @UrologySBUR]

TOMORROW—Don't miss the new SBUR Summer Trainee Webinar! Open to all SBUR members, this new platform will highlight trainee research. Join us on Friday, June 27 at 4:00 PM ET to learn more about prostate diseases.

Register here before it's too late: https://t.co/avmU8j3KNH